Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 17:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...